The medicines regulator has added two new safety warnings about mental health and contraception for people taking high-profile diabetes and weight loss drugs.
The Therapeutic Goods Administration (TGA) says that because suicidal behaviour and ideation have been reported with these relatively new GLP-1 receptor agonists, doctors should “monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviours, and/or any unusual changes in mood or behaviour”.
The warning of the potential risk of suicidal thoughts applies across the GLP-1 RA class of medicines, including Ozempic, Wegovy, Saxenda, Trulicity and Mounjaro.
Sign up: AU Breaking News email
The TGA has also issued a separate warning around Mounjaro and contraception.
After investigating the potential reduced effectiveness of oral contraception when first taking or increasing the dose of Mounjaro, the TGA said it could not rule out an association.
As a precautionary measure, it has updated the product warnings for Mounjaro to include further advice for patients using oral contraceptives to switch to a non-oral contraceptive or add a barrier method of contraception for four weeks after first taking the medicine and for four weeks after each increase in the dose.
It added that none of the GLP-1 RA class of medicine should be used during pregnancy.